within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DA05_PentaerithritylTetranitrate;

model PentaerithritylTetranitrate
  extends Pharmacolibrary.Drugs.ATC.C.C01DA05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01DA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pentaerithrityl tetranitrate (PETN) is an organic nitrate vasodilator used primarily for the prevention and treatment of angina pectoris. It acts as a nitric oxide donor, inducing vasodilation and reduced cardiac workload. While it has been used in some European countries, it is less commonly prescribed or approved in many regions today compared to other nitrates such as nitroglycerin or isosorbide mononitrate.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic models or detailed PK parameters for PETN as an antianginal agent in the general adult population have been identified in peer-reviewed literature sources.</p><h4>References</h4><ol><li><p>King, SY, &amp; Fung, HL (1986). Pharmacokinetics of pentaerythritol tetranitrate following intra-arterial and oral dosing in the rat. <i>Journal of pharmaceutical sciences</i> 75(3) 247–250. DOI:<a href=\"https://doi.org/10.1002/jps.2600750308\">10.1002/jps.2600750308</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3701607/\">https://pubmed.ncbi.nlm.nih.gov/3701607</a></p></li><li><p>Gilbert, JD, et al., &amp; Draffan, GH (1984). The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate. <i>Arzneimittel-Forschung</i> 34(10) 1323–1327. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6549136/\">https://pubmed.ncbi.nlm.nih.gov/6549136</a></p></li><li><p>Haustein, KO, et al., &amp; Hüller, G (1995). Absorption and bioavailability of pentaerithrityl-tetranitrate (PETN, Dilcoran 80). <i>International journal of clinical pharmacology and therapeutics</i> 33(2) 95–102. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7757318/\">https://pubmed.ncbi.nlm.nih.gov/7757318</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PentaerithritylTetranitrate;
